कंपनी का अवलोकन
Catheter Precision, Inc. (VTAK) is a specialized entity within the healthcare sector that focuses on the design, manufacturing, and sale of medical technologies specifically for cardiac electrophysiology in the United States. The company's primary operational asset is the View into Ventricular Onset System, a non-invasive imaging solution engineered to provide three-dimensional cardiac mapping capabilities for precise localization of cardiac issues. Operating within the broader medical devices industry, the firm serves a niche market requiring high-precision instrumentation for electrophysiological procedures. In terms of scale, the company currently holds a market capitalization of $2.32M and generates annual revenue of $819,000, while the specific number of employees is not disclosed in public filings. These valuation and revenue figures indicate that Catheter Precision operates as a small-cap entity with a relatively modest revenue base compared to larger peers in the medical technology landscape, suggesting a focus on niche product development rather than mass-market volume sales. The low market cap relative to the specialized nature of its products implies a high-risk, high-potential-reward profile typical of early-stage medical device innovators seeking to expand their technological footprint.
वित्तीय स्वास्थ्य
The company reported total revenue of $819,000 over the trailing twelve-month period, yet this gross income was offset by a net income loss of $17,183,000, revealing a significant divergence where operating expenses vastly exceeded total revenue. Additionally, the EBITDA stood at -$10,066,000, which further underscores the heavy cost structure associated with research, development, and administrative overheads that are common in the medical device industry before commercialization scales. The free cash flow position is negative at -$4,021,750, indicating that the company is burning cash reserves to fund its operations and product lifecycle rather than generating liquidity from core activities. Profitability metrics reflect this challenge, with a gross margin of 92.3% demonstrating high efficiency in production costs, contrasted sharply by an operating margin of -1204.2% and a profit margin of 0.0%, which signify substantial losses at the operational and net income levels. Regarding balance sheet leverage, the company holds only $88,000 in cash against total debt of $3.85M, creating a precarious liquidity situation exacerbated by a debt-to-equity ratio of 57.83. This leverage structure implies a highly leveraged financial position where debt obligations significantly outweigh equity capitalization. Liquidity analysis shows a current ratio of 0.10, meaning current assets are insufficient to cover current liabilities without external financing or asset liquidation. Furthermore, return metrics highlight the financial strain, with a return on equity of -192.3% and a return on assets of -34.9%, indicating that management efforts have resulted in negative returns on both shareholder equity and the asset base utilized to generate operations.
मूल्यांकन आकलन
Valuation multiples for Catheter Precision reflect its unprofitable status, evidenced by a trailing P/E ratio of N/A and a forward P/E of -0.23, which implies that traditional earnings-based valuation methods are inapplicable due to negative earnings expectations. The price-to-book ratio stands at 0.33, suggesting that the market values the company's equity at a fraction of its book value, a common characteristic for distressed or high-growth medical technology firms that have not yet realized profitability. Alternative valuation metrics such as the price-to-sales ratio of 2.83 and an EV/EBITDA of -0.56 provide insight into the company's valuation relative to its revenue generation and enterprise value, despite the negative earnings multiple. The stock price has experienced significant volatility, trading within a 52-week range with a high of $15.77 and a low of $0.85, indicating a wide spread that reflects market uncertainty regarding the company's path to profitability. The beta coefficient of 0.26 suggests that the stock's price volatility is substantially lower than the broader market, which is unusual for a small-cap stock and may indicate limited trading liquidity or a passive investor base. Investors should interpret these metrics carefully, as the negative forward P/E and negative EV/EBITDA point to a lack of current earnings power, while the low price-to-book ratio signals a deep discount relative to the recorded net assets on the balance sheet.
Growth & Income
Revenue growth demonstrates a robust trajectory with a year-over-year increase of 59.7%, which is a positive indicator of expanding market adoption or successful product penetration in the cardiac electrophysiology sector. Conversely, earnings growth is listed as N/A due to the company's persistent net losses, meaning that top-line revenue expansion has not yet translated into bottom-line profitability, a typical challenge for capital-intensive medical device firms in their growth phase. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is retained and reinvested into research, development, and operational scaling rather than distributed to shareholders. This reinvestment strategy is necessary given the negative free cash flow and the need to reduce the substantial debt load of $3.85M before the business can become a dividend-paying entity. Overall, the growth and income profile is characterized by strong revenue expansion coupled with significant operational losses and no income distribution, positioning the company as a pure growth play dependent on future commercial success to stabilize its financial health.